AKTX · XBRL financial data
Akari Therapeutics financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (AKTX's year ends in late December)
| In millions of dollars | Dec 31, 2022 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | year only | 3* | 2 | 3 | 0 | 1* | 1 | 1 | 0 | 1* | 1 | 2 |
| Selling, general and administrative | year only | 3* | 4 | 2 | 2 | 3* | 3 | 2 | 2 | 2* | 2 | 3 |
| Total operating expenses | year only | year only | 6 | — | — | year only | 4 | — | — | year only | 16 | — |
| Operating income (loss) | year only | (5)* | (6) | (7) | (3) | (5)* | (4) | (3) | (7) | (3)* | (16) | (5) |
| Interest income | year only | 0* | 0 | 0 | 0 | 0* | — | — | 0 | 0* | — | — |
| Interest expense | — | — | — | 0 | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 |
| Other income (expense) | year only | 0* | (0) | 0* | 0* | (0)* | — | — | — | — | — | — |
| Income tax expense (benefit) | year only | year only | 0 | — | — | year only | 0 | 0 | (1) | 0* | (1) | 0* |
| Net income (loss) | year only | (4)* | (6) | (8) | (3) | (4)* | (4) | (2) | (6) | (5)* | (14) | (5) |
| Earnings per share, basic USD per share | — | 0.00* | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
| Earnings per share, diluted USD per share | — | 0.00* | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
| Weighted average shares, basic millions of shares | — | 11,403* | 13,453 | 18,836 | 24,386 | — | 54,588 | 62,944 | 65,326 | — | 118,757 | 143,317 |
| Weighted average shares, diluted millions of shares | — | 11,306* | 13,453 | 18,836 | 24,386 | — | 54,588 | 62,944 | 65,326 | — | 118,757 | 143,317 |
Balance sheet
CSVFiscal quarters (AKTX's year ends in late December)
| In millions of dollars | Dec 31, 2022 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | 13 | 4 | 1 | 4 | 2 | 3 | 3 | 3 | 3 | 0 | 3 | 8 |
| Total current assets | 14 | 4 | 3 | 5 | 3 | 3 | 3 | 3 | 3 | 5 | 4 | 8 |
| Property and equipment, net | 0 | — | — | — | — | — | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | 8 | 8 | 8 | 8 | 8 | — | — |
| Total assets | 14 | 4 | 3 | 5 | 3 | 51 | 51 | 51 | 45 | 48 | 34 | 39 |
| Accounts payable | 1 | 2 | 3 | 5 | 5 | 12 | 13 | 12 | 11 | 9 | 9 | 9 |
| Accrued liabilities | 3 | 2 | 2 | 2 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 4 |
| Total current liabilities | — | 5 | 6 | 9 | 9 | 20 | 21 | 17 | 16 | 12 | 13 | 14 |
| Total liabilities | 12 | 5 | — | — | — | 28 | 29 | 25 | 23 | 20 | 20 | 20 |
| Accumulated deficit | (217) | (227) | (233) | (241) | (243) | (247) | (251) | (253) | (259) | (265) | (279) | (284) |
| Total stockholders' equity | 2 | (0) | (4) | (4) | (7) | 22 | 22 | 26 | 23 | 28 | 14 | 19 |
| Total liabilities and equity | 14 | 4 | 3 | 5 | 3 | 51 | 51 | 51 | 45 | 48 | 34 | 39 |
| Common shares outstanding (cover page) millions of shares | 7,445 | 15,847 | 15,847 | 23,907 | 49,517 | 57,753 | 64,353 | 65,229 | 71,479 | 91,567 | 91,567 | 155,759 |
Cash flows
CSVFiscal quarters (AKTX's year ends in late December)
| In millions of dollars | Dec 31, 2022 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | year only | (4)* | (6) | (8) | (3) | (4)* | (4) | (2) | (6) | (5)* | (14) | (5) |
| Stock-based compensation | year only | 0* | 0 | 0* | 0* | 1* | 1 | 1* | 1* | 0* | 0 | 1* |
| Depreciation and amortization | year only | 0* | 0 | 0* | 0* | 0* | — | — | — | — | — | — |
| Net cash from operating activities | year only | (4)* | (4) | (5)* | (1)* | (2)* | (2) | (3)* | (2)* | (3)* | (2) | (3)* |
| Net cash from investing activities | — | — | — | — | — | year only | — | — | — | — | — | — |
| Proceeds from issuing common stock | year only | 4* | 2 | 7* | (0)* | 3* | 2 | 4* | 0* | 5* | — | — |
| Net cash from financing activities | year only | 4* | 2 | 8* | (0)* | 2* | 2 | 3* | 2* | 6* | 0 | 8* |
| Net change in cash | year only | (1)* | (3) | 3* | (2)* | 0* | (0) | 0* | (0)* | 3* | (2) | 5* |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Akari Therapeutics | 7.7 | not reported | (3.1)* | 155.8B | 2.5 quarters | 10-QJun 30, 2026 |
| X4 Pharmaceuticals | 195 | 2.4 | (21)* | 99.1M | 9.4 quarters | 10-QJun 30, 2026 |
| ProPhase Labs | 0 | 1 | (0.1)* | 15.6M | 0.3 quarters | 10-QJun 30, 2026 |
| Pluri | 3.5 | 0.3* | (4.4)* | 12.3M | 0.8 quarters | 10-KJun 30, 2026 |
| CalciMedica | 19 | not reported | (4.6)* | 34.1M | 4.0 quarters | 10-QJun 30, 2026 |
| Edesa Biotech | 10 | not reported | (3.1)* | 9.6M | 3.3 quarters | 10-QJun 30, 2026 |
| GeoVax Labs | 3.1 | not reported | (3.7)* | 7.4M | 0.9 quarters | 10-QJun 30, 2026 |
| Lipocine | 5 | 0.2 | (3)* | 8.2M | 7.7 quarters | 10-QJun 30, 2026 |
| Earth Science Tech | 0.6 | 9 | 0.7 | 287.6M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.